Q3 2022
Released Oct 11, 2022, before the open
10-Q filed Nov 15, 2022, 46 days after period end · 0001493152-22-032511
Q3 2022 · 10-Q
Revenue$2.41M$2.41M −6.6% vs Q3 2021−15.5% vs Q2 2022
Net Income-$3.23M-$3.23M N/M vs Q3 2021N/M vs Q2 2022
EPS Diluted-$0.31-$0.31 N/M vs Q3 2021N/M vs Q2 2022
Gross Profit$762,000−44.0%
Operating Income-$1,281,000N/M
Operating Cash Flowderived-$170,000N/M
Free Cash Flowderived-$170,000N/M
Margins · derived
Gross margin31.6%−21.1 pt vs Q3 2021
Operating margin-53.2%−22.1 pt vs Q3 2021
Net margin-134.1%−86.7 pt vs Q3 2021
What the release said
The release
Same quarter
| Metric | Q3 2022 | Q3 2021 | Q3 2020 | Q3 2019 |
|---|---|---|---|---|
| Revenue | $2.41M | $2.58M | $2.12M | $3.10M |
| Net Income | -$3.23M | -$1.22M | -$1.01M | -$744.00K |
| EPS Diluted | -$0.31 | -$0.12 | -$0.12 | -$0.10 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Nephros Inc · CIK 1196298 · Engraved from SEC EDGAR